ALD 401

Drug Profile

ALD 401

Alternative Names: ALD401; ALDHbr

Latest Information Update: 13 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aldagen
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 05 May 2014 Discontinued - Phase-II for Stroke in USA (Intracarotid)
  • 31 Mar 2014 ALD 401 is available for licensing as of 31 Mar 2014.
  • 06 Jan 2014 Cytomedix completes enrolment in the phase III RECOVER-Stroke trial for Stroke in USA (NCT01273337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top